Search
ISIS 14803
go.drugbank.com/drugs/DB05803Investigationalantisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in
Mezlocillin
go.drugbank.com/drugs/DB00948ApprovedIt has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.
CR665
go.drugbank.com/drugs/DB05155ExperimentalIn addition, unlike currently marketed opioids, CR665 does not produce inhibition of intestinal transit (ileus), induce respiratory depression, or elicit signs of euphoria or addiction in animal models … In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound.
Lornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam is approved for use in Japan. … Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug.
Methaqualone
go.drugbank.com/drugs/DB04833ApprovedIllicitWithdrawnThe sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. … It has also been used illegally as a recreational drug, commonly known as Quaaludes, Sopors, Ludes or Mandrax (particularly in the 1970s in North America) depending on the manufacturer.
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
MLN0415
go.drugbank.com/drugs/DB05183ExperimentalIn preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.
KB002
go.drugbank.com/drugs/DB05194ExperimentalKB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.